(A) Gene expression of EMT-molecules with or without in vitro NextA treatment (5μM) on 4T1 cells by qPCR. (B) Expression of EMT-genes with or without in vitro NextA (5μM) on metastatic 4T1 lung-isolated clones by qPCR. (C) Expression of EMT-genes after in vitro NextA treatment (5μM) on MDA-MB-231 cells by qPCR. (D) Expression of EMT-genes after in vitro NextA treatment (5μM) on MCF7 cells by qPCR. (E) Evaluation of E-Cad levels in 4T1 cells after in vitro NextA treatment (5μM) by western blot. Evaluation of acetylated tubulin as an internal indicator for NextA mediated acetylation function. (F) Detection of the endogenous levels of E-Cad by western blot from in vivo tumor samples treated with NextA (25mg/kg). (G) Endogenous expression of HDAC6 and E-Cad protein in non-target vs. HDAC6KD-4T1 clones. (H) Corresponding E-Cad RNA levels in non-target vs. HDAC6KD-4T1 clones.. (I) Expression of EMT-genes in non-target and HDAC6KD-4T1 cells. (J) NextA dose-dependent invasion by 4T1 cells measured in 2D invasion chamber. GM-6001, a broad-spectrum MMP-inhibitor, is used as a positive control. (K) Quantification of wound closure of 4T1 cells throughout 16h, with or without NextA, as analyzed by ImageJ. (L) Snapshots of wound closure of 4T1 cells throughout 16h, with or without NextA, captured on Leica DMi8 microscope with a piezo stage (Pecon) with phase-contrast.